Olvanil

TargetMol
Product Code: TAR-T23106
Supplier: TargetMol
CodeSizePrice
TAR-T23106-1mg1mg£132.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T23106-2mg2mg£161.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T23106-5mg5mg£222.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T23106-10mg10mg£294.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T23106-25mg25mg£452.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T23106-50mg50mg£618.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T23106-100mg100mg£832.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T23106-500mg500mg£1,581.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Olvanil is a vanilloid receptor agonist with EC50 of 0.7nM.
CAS:
58493-49-5
Formula:
C26H43NO3
Molecular Weight:
417.634
Pathway:
Membrane transporter/Ion channel
Purity:
0.98
SMILES:
CCCCCCCCC=C/CCCCCCCC(=O)NCc1ccc(O)c(OC)c1
Target:
TRP/TRPV Channel

References

1. Giovanni Appendino, et al. Development of the first ultra-potent "capsaicinoid" agonist at transient receptor potential vanilloid type 1 (TRPV1) channels and its therapeutic potential. J Pharmacol Exp Ther. 2005 Feb;312(2):561-70. 2. S O Jacobsson, et al. Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors.J Pharmacol Exp Ther. 2001 Dec;299(3):951-9. 3. John W Kasckow, et al. Effects of the vanilloid agonist olvanil and antagonist capsazepine on rat behaviors. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Mar;28(2):291-5.